

Novel Nanotechnology-Based Antiviral Agents:

Silver nanoparticle neutralization of hemorrhagic fever viruses

Janice Speshock, Ph.D.
Saber Hussain, Ph.D.
Applied Biotechnology Branch
711th Human Performance Wing
Air Force Research Laboratory





Nanomaterials

Unique Properties

- Size (< 100nm)
- Optical (metal & Semiconductors
- Magnetic (metal)
- Surface reactivity
- Catalytic activity (high surface area)
- Bioaffinity
- Surface modification

DOD Applications

- Biosensors
- Antimicrobial Agents
- Munitions
- Propellants
- Coatings
- Smart Suits

Challenges

- Toxicity
- Reproducibility
- Stability of coatings/functional groups
- bioaffinity
- Effects on protein activity
- Effects on gene expression



Silver Nanoparticles


	UNCOATED	POLYSACCHARIDE COATED
10 nm	12.78 ± 0.13 Dr. Steve Oldenburg, NanoComposix	9.48 ± 4.286 Dr. Dan Goia, Clarkston University
25 nm	27.474 ± 9.062 Dr. Karl Martin, Novacentrix	25.98 ± 8.38 Dr. Dan Goia, Clarkston University



Hemorrhagic Fever Viruses


Arenaviridae

- South american HFV, Lassa Fever, LCMV
- Enveloped, RNA viruses
- No effective therapies
- Candid#1 vaccine
- 5-35% fatality rate




Filoviridae

- Ebola and Marburg
- Enveloped, RNA viruses
- No effective therapies
- Vaccine in Phase I trials
- Up to 90% fatality rate





Tacaribe Virus




- New World (Tacaribe) Complex
 - Junin, Machupo, Guanarito, and Sabia
- Tacaribe virus is a biochemically and serologically close relative of the CDC category A arenaviruses but has a low pathogenic potential for humans
- Experimentally:
 - Cytopathic effect in vero cells
 - lethal meningoencephalitis in mice






Arenavirus Experimental Setup






TCRV Progeny Virus Production

Tacaribe Virus Neutralization by Silver Nanoparticles






Cell Surface TCRV Expression






Dynamic Light Scattering





TCRV Internalization into Vero Cells




- Ag-NP-treated TCRV is internalized into infected Vero cells
- Ag-NPs and TCRV interact inside the cell lysosomes






TCRV Internalization into Vero Cells



Ag-NPs facilitate uptake of TCRV into Vero cells



Nucleoprotein RNA Expression



Mechanism of Ag-NP Inhibition packaging **vRNA** mRNA viral protein synthesis




- qRT-PCR detection of internalized eVLPs using Gp as a marker
- Confocal Microscopy of eVLP cell surface binding

- Confocal Microscopy of eVLP internalization
- Cathepsin B and L activity in Vero cells.



Ebola Virus-Like Particles


eVLP binding to Vero cells +/- Ag-NP



Concentration of Ag (µg/ml)




Cell Surface eVLP Expression






eVLP Internalization into Vero Cells






Cathepsin Activity

- Bulk and Nano Silver have been shown to inhibit enzyme activity.
- Silver binds readily to thiol groups.
- Cathepsin B has been shown to have an essential role in Ebola virus replication.
- Cathepsin L has an accessory role in Ebola virus replication.



Cathepsin B L. Jayashankar, Acharya Nagarjuna University , Guntur







Conclusions

- Ag-NPs neutralize TCRV infection
 - Decrease in S segment gene expression
 - Decrease in progeny virus production
- Ag-NPs do not prevent the internalization of TCRV
 - Ag-NPs and TCRV interact inside the cell
 - Mechanism of inhibition occurs between endocytosis and vRNA gene production
- Ag-NPs have a similar effect on eVLPs
- Ag-NPs decrease cathepsin activity



THE VICENCY ACENCY

Acknowledgements



Dr. Laura Braydich-Stolle, Craig Murdock, Eric Szymanski Dr. Amanda Schrand – not pictured

AFRL/RHPB BIN Group

Nanoparticles

- Dr. Karl Martin (Novacentrix, Austin, TX)
- Dr. Steven Oldenburg(NanoComposix, San Diego, CA)
- •Dr. Dan Goia (Clarkson University, Center for Advanced Materials Processing, Potsdam, NY)

Ebola virus-like particles

- Dr. Kelly Warfield (USAMRIID)
- Dr. Schlager (AFRL/RHPB) and Col. Reilly (AFRL/RH)
- Funding: DTRA (proposal #4.10036_07_AHB_B) & JSTO/DTRA NRC Postdoctoral Fellowship Program (contract #F49620-02-C-0015)





Comments/Questions